The consequences of thrombosis can be severe – pulmonary embolism (PE), myocardial infarction, stroke and infertility – and thrombosis is one of the most widespread causes of morbidity and mortality in developed countries. Hereditary thrombophilia, the propensity to develop thrombosis, is an important factor influencing development of deep vein thrombosis (DVT) and PE. Additional risk factors include pregnancy, prolonged immobilization, surgical intervention, injury and smoking.
The Astra Thrombosis kit enables identification of hereditary thrombophilia and estimation of a patient’s risk of developing DVT and PE. Following extraction of the patient’s total DNA sample from blood tissue or epithelium, three single nucleotide polymorphisms in the F5, F2 and MTHFR genes can be simultaneously detected using the kit. The method is multiplex PCR with subsequent restriction and polyacrylamide or agarose gel electrophoresis. The diagnostic kit includes two PCR mixes, positive controls, DNA-polymerase, restriction enzyme and buffer.
Testing for hereditary thrombophilia is recommended in various circumstances, such as venous embolism occurring before the age of 50, repeatedly, or during pregnancy or the postnatal period, and for members of families with expressed hereditary thrombophilia.
About Astra Biotech GmbH
Astra Biotech GmbH is a quality-focused company with its success in developing in vitro diagnostic assays for laboratories specialising in multiple medical fields founded on dependable science and strong relationships. The range of CE-labelled products available includes reagents for detecting and calibrating human hormones, kits for genetic diseases, tumour markers, allergens, as well as conjugates, antibodies, and recombinant proteins.
For sales information contact:
Alexandra Ghica-Cantacuzino
Astra Biotech GmbH
Tel: +49 3371681457
Email: sales@astrabiotech.de
www.astrabiotech.de
Media Contact:
Phoenix MarCom Ltd
Tel: + 44 (0) 1223 873318
Fax: + 44 (0) 1223 874173
Email: marketing@phoenixmarcom.co.uk
